Phreesia, Inc. (NYSE:PHR) Short Interest Up 21.0% in March

Phreesia, Inc. (NYSE:PHR) was the target of a large growth in short interest in the month of March. As of March 13th, there was short interest totaling 4,404,667 shares, a growth of 21.0% from the February 26th total of 3,639,021 shares. Based on an average daily volume of 1,474,342 shares, the days-to-cover ratio is presently 3.0 days. Approximately 7.7% of the shares of the stock are sold short.

More Phreesia News

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Q4 operating results showed revenue growth and much stronger free cash flow, giving a fundamental floor under the shares; transcripts and presentations highlight record revenue growth and improving FCF. Earnings Presentation
• Positive Sentiment: Stephens lowered its price target but kept an “overweight” stance (new PT $20), signaling some analysts still see sizable upside from current levels despite weaker guidance. Stephens Coverage
• Neutral Sentiment: Multiple firms reiterated neutral/hold or market‑perform ratings (JPMorgan, Robert W. Baird, Citigroup, Truist, Citizens Jmp) while trimming price targets — this keeps the stock in analysts’ coverage but signals cautious sentiment. Analyst Radar
• Negative Sentiment: Management cut FY2027 revenue guidance to $510M–$520M (from $545M–$559M), citing reduced visibility into pharma client spending and weaker H2 commitments — the guidance cut is the primary driver of recent heavy selling. Guidance Coverage
• Negative Sentiment: Shares plunged after the outlook cut and several firms lowered price targets (examples: Needham, BMO, Canaccord lowered targets; multiple downgrades and PT trims followed the guidance update), increasing near-term downside risk. Downgrades Coverage
• Negative Sentiment: Levi & Korsinsky has opened an investigation into potential securities-law violations related to Phreesia, introducing legal/uncertainty risk that can amplify volatility and weighing on sentiment. Investigation Notice
• Negative Sentiment: Some sell-side commentary withdrew buy recommendations or explicitly flagged disappointment with the growth outlook, which can pressure flows and limit short‑term buyers. Analyst Reaction

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Robert W. Baird reiterated a “neutral” rating and issued a $10.00 price target (down from $25.00) on shares of Phreesia in a research note on Tuesday. Royal Bank Of Canada assumed coverage on Phreesia in a research report on Friday, January 9th. They set a “moderate buy” rating and a $26.00 price objective for the company. Mizuho reduced their target price on Phreesia from $22.00 to $19.00 and set an “outperform” rating on the stock in a report on Tuesday, March 24th. Citigroup reissued a “neutral” rating and set a $10.00 price target (down from $25.00) on shares of Phreesia in a research note on Tuesday. Finally, Stephens cut their price target on Phreesia from $32.00 to $20.00 and set an “overweight” rating for the company in a report on Tuesday. Twelve research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $22.00.

Insider Buying and Selling at Phreesia

In other news, General Counsel Allison C. Hoffman sold 6,176 shares of Phreesia stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $11.97, for a total transaction of $73,926.72. Following the sale, the general counsel owned 163,485 shares in the company, valued at $1,956,915.45. This trade represents a 3.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Balaji Gandhi sold 3,829 shares of the business’s stock in a transaction on Wednesday, March 25th. The stock was sold at an average price of $11.26, for a total transaction of $43,114.54. Following the completion of the transaction, the chief financial officer directly owned 146,740 shares in the company, valued at $1,652,292.40. This trade represents a 2.54% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 70,358 shares of company stock worth $1,123,569. Insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Phreesia

Several large investors have recently added to or reduced their stakes in PHR. Federated Hermes Inc. purchased a new stake in Phreesia during the third quarter valued at approximately $32,000. Van ECK Associates Corp boosted its holdings in shares of Phreesia by 78.7% in the 4th quarter. Van ECK Associates Corp now owns 2,502 shares of the company’s stock worth $42,000 after purchasing an additional 1,102 shares during the period. Asset Management One Co. Ltd. purchased a new position in shares of Phreesia in the 3rd quarter worth approximately $45,000. Rockefeller Capital Management L.P. increased its position in shares of Phreesia by 354.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 2,755 shares of the company’s stock valued at $47,000 after purchasing an additional 2,149 shares during the last quarter. Finally, KBC Group NV increased its position in shares of Phreesia by 83.4% during the 4th quarter. KBC Group NV now owns 3,449 shares of the company’s stock valued at $58,000 after purchasing an additional 1,568 shares during the last quarter. 92.10% of the stock is owned by institutional investors.

Phreesia Price Performance

PHR stock opened at $8.40 on Thursday. Phreesia has a 52 week low of $7.77 and a 52 week high of $32.76. The firm has a market capitalization of $506.35 million, a P/E ratio of 279.97 and a beta of 0.67. The company has a fifty day simple moving average of $12.21 and a two-hundred day simple moving average of $17.51. The company has a quick ratio of 2.44, a current ratio of 2.44 and a debt-to-equity ratio of 0.01.

Phreesia (NYSE:PHR) last posted its earnings results on Monday, March 30th. The company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.05). The business had revenue of $127.07 million during the quarter, compared to the consensus estimate of $126.75 million. Phreesia had a return on equity of 3.33% and a net margin of 0.48%.The business’s quarterly revenue was up 15.9% on a year-over-year basis. During the same quarter last year, the firm earned ($0.11) earnings per share. Analysts anticipate that Phreesia will post -1.1 earnings per share for the current fiscal year.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.